Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FASIHA KANWAL and SAIRA KHADERI.
FASIHA KANWAL
Connection Strength
2.856
SAIRA KHADERI
  1. Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology. 2022 09; 76(3):546-548.
    View in: PubMed
    Score: 0.835
  2. Project ECHO: The Specialist Will See You Now. Hepatology. 2018 12; 68(6):2066-2068.
    View in: PubMed
    Score: 0.657
  3. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.230
  4. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.224
  5. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.221
  6. Cirrhosis Quality Collaborative. Clin Gastroenterol Hepatol. 2022 05; 20(5):970-972.
    View in: PubMed
    Score: 0.206
  7. Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis. Gastroenterology. 2024 Nov 07.
    View in: PubMed
    Score: 0.062
  8. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2024 Jun 19.
    View in: PubMed
    Score: 0.061
  9. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.060
  10. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024 Feb 16.
    View in: PubMed
    Score: 0.059
  11. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.055
  12. Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplant Direct. 2022 May; 8(5):e1313.
    View in: PubMed
    Score: 0.052
  13. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol. 2020 Sep 27; 12(9):628-640.
    View in: PubMed
    Score: 0.047
  14. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.045
  15. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.